



Frontiers in Shigella Vaccine Development

Guest Editors:

Dr. Duncan Steele

Enteric and Diarrheal Disease, Bill
& Melinda Gates Foundation,
Seattle, WA 98102, USA

Prof. Calman A. MacLennan

Bill and Melinda Gates
Foundation, Seattle, WA 98109,
USA

Deadline for manuscript
submissions:

closed (1 January 2022)

Message from the Guest Editors

Dear Colleagues,

Based on the burden of *Shigella* infections in young children in low- and lower-middle-income countries, there has been much activity in the development of *Shigella* vaccines for global health vaccines in recent years.

In addition, there have been important advances in aligned activities that will be needed for the licensure, prequalification, and ultimately introduction of these new *Shigella* vaccines. These activities include the harmonization of *Shigella* CHIM, standardization of a *Shigella* ELISA, steps towards the development of a first international standard serum, development of a *Shigella* vaccine value proposition, exploratory of pathways to licensure, and regulatory considerations, and preparation of potential sites for a phase-3 efficacy trial.

This Special Issue titles will serve to update the vaccine and infectious diseases communities on the recent progress in this area and help provide a line of sight through to the licensure of the first global health *Shigella* vaccines.

Dr. Duncan Steele
Prof. Calman A. MacLennan
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com